BR112012002246A2 - composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente - Google Patents
composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um pacienteInfo
- Publication number
- BR112012002246A2 BR112012002246A2 BR112012002246A BR112012002246A BR112012002246A2 BR 112012002246 A2 BR112012002246 A2 BR 112012002246A2 BR 112012002246 A BR112012002246 A BR 112012002246A BR 112012002246 A BR112012002246 A BR 112012002246A BR 112012002246 A2 BR112012002246 A2 BR 112012002246A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- akzhmer
- inhibiting
- disease
- patient
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 230000006999 cognitive decline Effects 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/25—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/05—Alcohols containing rings other than six-membered aromatic rings
- C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/28—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
- C07C33/30—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/18—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23032609P | 2009-07-31 | 2009-07-31 | |
| US30868610P | 2010-02-26 | 2010-02-26 | |
| PCT/US2010/044136 WO2011014880A1 (en) | 2009-07-31 | 2010-08-02 | Inhibitors of cognitive decline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012002246A2 true BR112012002246A2 (pt) | 2019-09-24 |
Family
ID=43529740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012002246A BR112012002246A2 (pt) | 2009-07-31 | 2010-08-02 | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9192585B2 (enExample) |
| EP (1) | EP2458983B1 (enExample) |
| JP (1) | JP2013501006A (enExample) |
| CN (1) | CN102595884B (enExample) |
| AU (2) | AU2010278711A1 (enExample) |
| BR (1) | BR112012002246A2 (enExample) |
| DK (1) | DK2458983T3 (enExample) |
| ES (1) | ES2547730T3 (enExample) |
| IL (1) | IL217833A0 (enExample) |
| RU (1) | RU2012107457A (enExample) |
| SG (2) | SG10201506978UA (enExample) |
| WO (1) | WO2011014880A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2545795T3 (es) | 2009-04-09 | 2015-09-15 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
| EP2458983B1 (en) | 2009-07-31 | 2015-07-08 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20130071330A1 (en) * | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| EP2670402B1 (en) * | 2011-02-02 | 2017-09-20 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| EP2690969B1 (en) * | 2011-03-29 | 2018-10-03 | Council of Scientific & Industrial Research | Process for the modification of curcuma aromatica essential oil |
| GB201111319D0 (en) | 2011-07-04 | 2011-08-17 | Univ Leuven Kath | Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa |
| JP2014524482A (ja) * | 2011-08-25 | 2014-09-22 | コグニション セラピューティクス，インコーポレイテッド | 神経変性疾患を処置する組成物及び方法 |
| HK1202246A1 (en) * | 2011-08-25 | 2015-09-25 | 考格尼申治疗股份有限公司 | Compositions and methods for treating neurodegenerative disease |
| DK3099296T3 (en) | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| AU2018269964B2 (en) | 2017-05-15 | 2022-07-07 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA732136B (en) | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
| US4321386A (en) | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
| EP0117647B1 (en) | 1983-01-31 | 1988-08-17 | Eli Lilly And Company | Improvements in or relating to phenethanolamines |
| JPS62283922A (ja) | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
| US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| US4958029A (en) | 1987-01-13 | 1990-09-18 | Banyu Pharmaceutical Co., Ltd. | Process for the production of isoindoline derivatives, novel intermediates and process for their production |
| JPH01180822A (ja) | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
| JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法 |
| JPH045266A (ja) | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
| DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE4123341A1 (de) * | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| AU702629B2 (en) | 1991-08-23 | 1999-02-25 | Nps Pharmaceuticals, Inc. | Calcium receptor-active arylalkyl amines |
| US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| CZ290670B6 (cs) | 1994-10-21 | 2002-09-11 | Nps Pharmaceuticals, Inc. | Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje |
| JP3522930B2 (ja) * | 1995-12-06 | 2004-04-26 | 花王株式会社 | 抗菌剤及びこれを含有する口腔用組成物 |
| WO1997030038A1 (en) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Diarylsultam derivatives |
| US6235731B1 (en) | 1996-04-24 | 2001-05-22 | Takeda Chemical Industries, Ltd. | Fused imidazopyridine derivatives as antihyperlipidemic agents |
| US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| AU2300001A (en) | 1999-10-22 | 2001-05-08 | Board Of Trustees Of The University Of Illinois, The | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
| JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
| US20030073681A1 (en) | 2001-08-21 | 2003-04-17 | Hauske James R. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| US6991814B2 (en) * | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| EA007067B1 (ru) | 2001-12-14 | 2006-06-30 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Композиция для лечения нейроцереброваскулярных нарушений |
| JP2004002517A (ja) | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
| DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
| US7863272B2 (en) | 2003-06-12 | 2011-01-04 | M's Science Corporation | Sigma ligands for neuronal regeneration and functional recovery |
| AU2004317129A1 (en) | 2004-03-12 | 2005-09-22 | Egis Gyogyszergyar Nyrt. | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
| JPWO2005115366A1 (ja) * | 2004-05-31 | 2008-03-27 | 株式会社カネカ | ウコン精油成分を含有する生活習慣病予防・改善剤 |
| ES2415665T3 (es) | 2004-06-21 | 2013-07-26 | Proteome Sciences Plc | Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| JP2008512417A (ja) | 2004-09-10 | 2008-04-24 | ユセベ ファルマ ソシエテ アノニム | シグマ受容体リガンド |
| US20060153772A1 (en) | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| US20090035295A1 (en) | 2005-03-05 | 2009-02-05 | Abbott Gmgh & Co. Kg | Screening Method, Process for Purifying of Non-Diffusible A-Beta Oligomers, Selective Antibodies Against Said Non-Diffusible a-Beta Oligomers and a Process for Manufacturing of Said Antibodies |
| KR20080041624A (ko) | 2005-06-15 | 2008-05-13 | 대릭 에스. 에치. 엘. 김 | 베타-아밀로이드 단백질-유발 안질환의 치료 방법 |
| EP1745778A3 (en) | 2005-07-20 | 2007-03-07 | Speedel Experimenta AG | Diaminoalcohols as therapeutic compounds |
| ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
| KR20090007564A (ko) * | 2006-03-17 | 2009-01-19 | 허발사이언스 싱가포르 피티이 리미티드 | 쿠르쿠마 종을 포함한 추출물 및 이를 수득하는 방법 |
| WO2007112288A2 (en) | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
| US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
| WO2008042755A2 (en) | 2006-09-29 | 2008-04-10 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
| US7968524B2 (en) | 2007-05-15 | 2011-06-28 | Helicon Therapeutics, Inc. | Methods of enhancing long term memory formation by inhibition of Gpr12 |
| CN101121670A (zh) | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
| ES2498065T3 (es) | 2007-10-24 | 2014-09-24 | Astellas Pharma Inc. | Compuesto de azolcarboxamida o sal del mismo |
| WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
| EP2138104A1 (en) | 2008-06-25 | 2009-12-30 | Vibra Tech AB | Core biopsy arrangement |
| KR101515822B1 (ko) | 2008-11-29 | 2015-04-29 | 더 타일랜드 리서치 펀드 | 바이러스와 타겟 세포의 상호작용 저해 |
| WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
| DK3255146T3 (da) | 2009-03-16 | 2019-08-19 | Pangu Biopharma Ltd | Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter |
| ES2545795T3 (es) | 2009-04-09 | 2015-09-15 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
| EP2458983B1 (en) | 2009-07-31 | 2015-07-08 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20130071330A1 (en) | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| JP2014524482A (ja) | 2011-08-25 | 2014-09-22 | コグニション セラピューティクス，インコーポレイテッド | 神経変性疾患を処置する組成物及び方法 |
-
2010
- 2010-08-02 EP EP10805177.2A patent/EP2458983B1/en active Active
- 2010-08-02 ES ES10805177.2T patent/ES2547730T3/es active Active
- 2010-08-02 DK DK10805177.2T patent/DK2458983T3/en active
- 2010-08-02 BR BR112012002246A patent/BR112012002246A2/pt not_active IP Right Cessation
- 2010-08-02 SG SG10201506978UA patent/SG10201506978UA/en unknown
- 2010-08-02 JP JP2012523127A patent/JP2013501006A/ja active Pending
- 2010-08-02 US US13/388,128 patent/US9192585B2/en active Active
- 2010-08-02 AU AU2010278711A patent/AU2010278711A1/en not_active Abandoned
- 2010-08-02 SG SG2012006805A patent/SG178191A1/en unknown
- 2010-08-02 WO PCT/US2010/044136 patent/WO2011014880A1/en not_active Ceased
- 2010-08-02 RU RU2012107457/04A patent/RU2012107457A/ru not_active Application Discontinuation
- 2010-08-02 CN CN201080043697.0A patent/CN102595884B/zh not_active Expired - Fee Related
-
2012
- 2012-01-30 IL IL217833A patent/IL217833A0/en unknown
-
2015
- 2015-10-12 AU AU2015242947A patent/AU2015242947B2/en not_active Ceased
- 2015-10-16 US US14/885,768 patent/US9815770B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2458983B1 (en) | 2015-07-08 |
| CN102595884B (zh) | 2014-12-03 |
| US9192585B2 (en) | 2015-11-24 |
| EP2458983A4 (en) | 2012-12-19 |
| IL217833A0 (en) | 2012-03-29 |
| HK1171624A1 (en) | 2013-04-05 |
| DK2458983T3 (en) | 2015-10-05 |
| AU2010278711A1 (en) | 2012-02-23 |
| ES2547730T3 (es) | 2015-10-08 |
| AU2015242947A1 (en) | 2015-10-29 |
| WO2011014880A1 (en) | 2011-02-03 |
| JP2013501006A (ja) | 2013-01-10 |
| US20160137588A1 (en) | 2016-05-19 |
| RU2012107457A (ru) | 2013-09-10 |
| US9815770B2 (en) | 2017-11-14 |
| SG178191A1 (en) | 2012-03-29 |
| US20120129945A1 (en) | 2012-05-24 |
| EP2458983A1 (en) | 2012-06-06 |
| CN102595884A (zh) | 2012-07-18 |
| AU2015242947B2 (en) | 2017-09-28 |
| SG10201506978UA (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012002246A2 (pt) | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| BRPI0821274A2 (pt) | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
| BRPI1009860A2 (pt) | composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais | |
| BRPI0811534A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo. | |
| IL221795B (en) | Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates | |
| BRPI0918337A2 (pt) | composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso | |
| IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
| BRPI0715888A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de mtor e um efeito anti-câncer em um animal de sangue quente e para tratar doenças em um animal de sangue quente. | |
| BR112013030045A2 (pt) | composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente | |
| BR112012003464A2 (pt) | composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio." | |
| BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
| BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI1014174A2 (pt) | uso de um composto da fórmula (i),(ii),(iii), ou (iv) ou um sal farmaceuticamente aceitável seu para a fabricação de um medicamento para o tratamento de câncer em um humano ou um animal; método para o tratamento de câncer, pacote comercial, método para redução de células cancerosas e kit para o tratamento de câncer | |
| BR112012003462A2 (pt) | "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase." | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0907992A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, uso do mesmo, composição farmacêutica, método de terapia em um animal de sangue quente, e, processo para preparar um composto | |
| BRPI0720169A2 (pt) | Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto | |
| PL2401263T3 (pl) | Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu | |
| ZA201203281B (en) | Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals | |
| BRPI0910737A2 (pt) | composto, pró-droga, agente farmacêutico, método para profilaxia ou tratamento de doenças do trato urinário inferior em um mamífero, e, uso de um composto ou uma pró-droga do mesmo. | |
| BRPI0908883A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| IL215840A (en) | Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases | |
| ZA201303695B (en) | Pharmaceutical composition comprising citrate and bicarbonate salts,and use thereof for treating cystinuria | |
| BRPI0913854A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para o tratamento, a prevenção ou o alívio de uma doença ou um distúrbio ou uma condição de um organismo de animal vivente. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |